BBIO changes
Pick any two versions below to diff them.
- Price
- $76.03
- Discount category
- Close to intrinsic value
- Next earnings
- Feb 23, 2027
- Next earnings is estimate
- Yes
- Company name
- added: BridgeBio Pharma
- Sector
- added: Biotechnology: medicines for genetic diseases
- About
- added: BridgeBio Pharma, Inc. (BridgeBio) is based in Palo Alto, California. It develops medicines for genetic diseases. Its product Attruby (acoramidis) treats transthyretin amyloid cardiomyopathy (ATTR-CM). Bayer sells acoramidis as BEYONTTRA in Europe and Japan and pays royalties and milestones. BridgeBio has three more medicines under FDA Priority Review: BBP-418 for limb-girdle muscular dystrophy type 2I/R9, oral infigratinib for achondroplasia and encaleret for autosomal dominant hypocalcemia type 1 (ADH1). Total revenues were $353.2 million in Q3 2026, of which US Attruby net product revenue was $253.2 million. The common stock trades on Nasdaq in US dollars. BridgeBio files 10-K and 10-Q reports.
- Thesis
- added: BridgeBio still loses money, so its price depends on how fast Attruby sales grow and on whether its three new medicines get approved and sell. US Attruby net product revenue rose to $253.2 million in Q3 2026 from $108.1 million a year before. The loss from operations was $11.6 million in Q3, with a one-time milestone of $75.0 million from Bayer, and $224.7 million for nine months. Large claims come before the common stock: convertible notes of $2,505 million in principal, deferred royalty obligations of $884.1 million and Series A preferred stock with a liquidation preference of $1,134.4 million. For the price to rise, three things must be true. Attruby must keep taking share from tafamidis in ATTR-CM. The FDA must approve BBP-418 by November 27, 2026, oral infigratinib by February 4, 2027 and encaleret by May 8, 2027, and the launches must sell. Operating costs must grow slower than revenue, so that BridgeBio earns a steady profit. The three FDA decisions and the Q4 2026 report in February 2027 are the next tests.
- Risks
- added: Large claims come before the common stock. At September 30, 2026, convertible notes were $2,505 million in principal, deferred royalty obligations were $884.1 million and the Series A preferred stock had a liquidation preference of $1,134.4 million. Three FDA decisions are close. The FDA can reject or delay BBP-418, oral infigratinib or encaleret, and an approved medicine can sell less than planned. Attruby competes with other ATTR-CM medicines, such as tafamidis. US price rules, such as most-favored-nation pricing, can lower its net price. The share count can grow. The notes can convert into about 37.8 million shares and the preferred stock into about 6.8 million shares, and options and stock units add about 18.1 million more. Milestone revenue is uneven. The $75.0 million Bayer milestone lifted Q3 2026 revenues, and such payments do not repeat each quarter.
- Balance sheet
- added: Cash: $1.5B Debt: $2.5B Net debt: $966M Debt due within 12 months: $550M Last debt due: 2033 At September 30, 2026, BridgeBio had cash, cash equivalents and marketable securities of $1,538.9 million. Convertible notes were $2,505 million in principal: $550.0 million of 2.50% notes due March 15, 2027, $747.5 million due 2029, $575.0 million due 2031 and $632.5 million due 2033. The 2027 notes are in current liabilities and holders can convert them from October 1 to December 14, 2026 and after December 15, 2026. Deferred royalty obligations of $884.1 million are not in the debt tile. The Series A preferred stock of 933,900 shares had a liquidation preference of $1,134.4 million. Net cash used in operating activities was $312.6 million in nine months of 2026, and the company repurchased common stock for $252.5 million. The total stockholders' deficit was $1,652.1 million. As of Sep 30, 2026.
- Checkpoints
- added: Nov 27, 2026: FDA decision on BBP-418. Pending. Watch: The FDA approves BBP-418 for limb-girdle muscular dystrophy type 2I/R9 by November 27, 2026, and this passes; a rejection or a delay fails. Feb 4, 2027: FDA decision on oral infigratinib. Pending. Watch: The FDA approves oral infigratinib for achondroplasia by February 4, 2027, and this passes; a rejection or a delay fails. Feb 23, 2027 (estimate): Q4 2026 results. Pending. Watch: US Attruby net product revenue grows again from the $253.2 million of Q3 2026, and this passes; flat or lower revenue fails. May 8, 2027: FDA decision on encaleret. Pending. Watch: The FDA approves encaleret for ADH1 by May 8, 2027, and this passes; a rejection or a delay fails.
- Recent events
- added: Oct 29, 2026: BridgeBio reported Q3 2026 results. Total revenues were $353.2 million, against $120.7 million a year before, and US Attruby net product revenue was $253.2 million. Revenues included a sales milestone of $75.0 million from Bayer. The loss from operations was $11.6 million. Cash, cash equivalents and marketable securities were $1.5 billion. Oct 6, 2026: The FDA accepted the application for oral infigratinib in achondroplasia with Priority Review. The target action date is February 4, 2027. Aug 31, 2026: BridgeBio announced an agreement with the US government on the prices of medicines. It expects its price commitment for future medicines to exclude medicines approved only for orphan diseases. Aug 13, 2026: KKR Genetic Disorder L.P. sold 5,000,000 shares of BridgeBio at $78.00 per share. BridgeBio received no proceeds. Jul 22, 2026: The FDA accepted the application for encaleret in ADH1. The target action date is May 8, 2027. Jul 1, 2026: BridgeBio sold 933,900 shares of Series A convertible preferred stock for $933.9 million to funds of Sixth Street Partners and HealthCare Royalty. The preferred stock accrues dividends at 7.00% a year at first and converts at $137.79 per share. May 27, 2026: The FDA accepted the application for BBP-418 in limb-girdle muscular dystrophy type 2I/R9 with Priority Review. The target action date is November 27, 2026. Jan 21, 2026: BridgeBio issued $632.5 million of convertible notes due 2033, with a conversion price of about $110.58 per share.